Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex Incorporated (NYSE: TFX) will feature its Chairman, President, and CEO, Liam Kelly, at the Bank of America Securities 2023 Health Care Conference. This event is set for May 9, 2023, at 10:00 a.m. (PT), held at the Encore Hotel in Las Vegas, Nevada. Attendees can access a live audio webcast of the presentation on the Teleflex investor website.
Teleflex specializes in medical technologies aimed at enhancing health and quality of life, offering solutions in vascular access, cardiology, anesthesia, and more. Their innovative approaches address critical clinical needs, benefiting patients and healthcare professionals alike.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
